The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
Rachel A. Freedman
Research Funding - Puma Biotechnology
Rebecca Sue Gelman
No relevant relationships to disclose
Jeffrey Scott Wefel
No relevant relationships to disclose
Ian E. Krop
Consultant or Advisory Role - Puma Biotechnology (U)
Michelle E. Melisko
No relevant relationships to disclose
Alarice Lowe
No relevant relationships to disclose
Nathalie Agar
Employment or Leadership Position - BayesianDx
Consultant or Advisory Role - BayesianDx
Kimberly L. Blackwell
No relevant relationships to disclose
Roisin M. Connolly
No relevant relationships to disclose
Polly Ann Niravath
No relevant relationships to disclose
Catherine H. Van Poznak
No relevant relationships to disclose
Shannon Puhalla
Consultant or Advisory Role - Celldex; MedImmune; Pfizer
Nicole Ryabin
No relevant relationships to disclose
Elizabeth S Lawler
No relevant relationships to disclose
Nuhad K. Ibrahim
No relevant relationships to disclose
Minetta C. Liu
No relevant relationships to disclose
Antonio C. Wolff
Research Funding - Roche/Genentech
Eric P. Winer
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Nancy U. Lin
Consultant or Advisory Role - Genentech (U); Novartis
Research Funding - Array BioPharma; Genentech; GlaxoSmithKline; Novartis